Alexis Finkelberg Bortniker

Cooley advised EliseAI, an artificial intelligence company automating complex healthcare and housing systems, on the close of its $250 million Series E financing.

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Medically Home, a provider of a hospital-at-home technology enablement model for health systems and physician groups to safely deliver emergency and hospital-level care at home, on its merger with DispatchHealth, a provider of high-acuity, in-home medical care for people experiencing serious health concerns. 

Cooley advised Oberland Capital, a private investment firm committed to funding innovation across the global healthcare industry, on its agreement to invest up to $600 million in Biohaven (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases.

Cooley advised Machinify, a provider of artificial intelligence-powered software transforming healthcare payments, on its definitive agreement to be acquired by New Mountain Capital.